|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 74 Windy Hollow Court |
Address2 |
|
| City | Great Falls |
State | VA |
Zip Code | 22066 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 401108536-60141
|
||||||||
|
6. House ID# 565120001
|
||||||||
| TYPE OF REPORT | 8. Year | 2024 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Kathleen Jaeger |
Date | 3/5/2025 1:42:18 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
IPA seeks to establish a U.S.-India trade partnership to de-risk the affordable medicine supply chain, including Key Starting Materials (KSMs) and Active Pharmaceutical Ingredients (APIs). This initiative aims to extend to other trusted allies, enhancing global supply chain resilience. The partnership focuses on industry sustainability, quality metrics, market demand, and boosting domestic and allied manufacturing with a suite of financial tools. Additionally, IPA seeks to advocate for middlemen reform and sustainability in the pharmaceutical sector, ensuring long-term viability and accessibility of affordable medicines.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), Natl Security Council (NSC), Health & Human Services - Dept of (HHS), White House Office, U.S. Trade Representative (USTR), State - Dept of (DOS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kathleen |
Jaeger |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
IPA is a trade association based in India, representing global manufacturers of both innovative and affordable medicines. These key industry players are instrumental in the U.S. healthcare market, supplying nearly 50% of the medicine for U.S. Medicare program. Also, in the top 10 therapeutic categories in the U.S., IPA member companies provide more than half of the prescriptions for five of these categories, with their market share in some categories reaching up to 60%. This significant contribution underscores IPA's crucial role as America's Medicine partner, ensuring access to affordable medications, thereby supporting America's health.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
IPA champions a U.S.-India trade partnership to de-risk the affordable medicine supply chain, including Key Starting Materials (KSMs) and Active Pharmaceutical Ingredients (APIs). This initiative aims to extend to other trusted allies, enhancing global supply chain resilience. The partnership focuses on industry sustainability, quality metrics, market demand, and boosting domestic and allied manufacturing with a suite of financial tools
17. House(s) of Congress and Federal agencies Check if None
U.S. Trade Representative (USTR), U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, State - Dept of (DOS), Natl Security Council (NSC)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kathleen |
Jaeger |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
IPA: a trade association based in India, representing global manufacturers of both innovative and affordable medicines.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code DEF
16. Specific lobbying issues
IPA champions a U.S.-India affordable medicine trade partnership to drive national security and de-risk the affordable medicine supply chain, including Key Starting Materials (KSMs) and Active Pharmaceutical Ingredients (APIs). This initiative aims to extend to other trusted allies, enhancing global supply chain resilience.
17. House(s) of Congress and Federal agencies Check if None
Natl Security Council (NSC), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kathleen |
Jaeger |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
IPA: a trade association based in India, representing global manufacturers of both innovative and affordable medicines.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HOM
16. Specific lobbying issues
IPA champions a U.S.-India trade partnership to drive national security and de-risk the affordable medicine supply chain, including Key Starting Materials (KSMs) and Active Pharmaceutical Ingredients (APIs). This initiative aims to extend to other trusted allies, enhancing global supply chain resilience.
17. House(s) of Congress and Federal agencies Check if None
Natl Security Council (NSC)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kathleen |
Jaeger |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
IPA:a trade association based in India, representing global manufacturers of both innovative and affordable medicines.
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address | A-205 Sangam Building 14B, SV Road, Santacruz West |
||||||
| City | Mumbai |
State |
|
Zip Code | 4000 054 |
Country | IND |
21. Client new principal place of business (if different than line 20)
| City | Great Falls, VA |
State | VA |
Zip Code | 22066 |
Country | USA |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
TRD |
HCR |
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |